Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting

Molecular Interventions

Volumn 5, Issue 6, 2005, Pages 343-357

  Hall, Julie M ^a   McDonnell, Donald P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Departmental Graduate Studies Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; AMINO ACID; ANTIESTROGEN; CELL NUCLEUS RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DNA; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; FULVESTRANT; IDOXIFENE; LEUCINE; NAFOXIDINE; NUCLEAR RECEPTOR COACTIVATOR 2; NUCLEAR RECEPTOR COREPRESSOR; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN E6; RALOXIFENE; RECEPTOR INTERACTING PROTEIN 140; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TRANSCRIPTION FACTOR;

BIOLOGICAL ACTIVITY; BIOLOGY; BREAST TUMOR; CANCER; CELL NUCLEUS; CHROMATIN CONDENSATION; DRUG ACTIVITY; HUMAN; MOLECULAR MECHANICS; MOLECULAR PROBE; NONHUMAN; PATHOPHYSIOLOGY; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UTERUS CANCER;

AMINO ACID MOTIFS; ANIMALS; BREAST NEOPLASMS; CELL NUCLEUS; CHROMATIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; REPRESSOR PROTEINS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 30344479480     PISSN: 15340384     EISSN: None     Source Type: Journal    
DOI: 10.1124/mi.5.6.7     Document Type: Review

References (78)

1. Mangelsdorf, D.J. Thummel, C., Beato, M. et al. The nuclear receptor super-family: The second decade. Cell 83, 835-839 (1995). This review provides an excellent introduction to the nuclear receptor field.
2. Hall, J.M., Couse, J.F., and Korach, K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276, 36869-36872 (2001).
3. Kuiper, G.G., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138, 863-870 (1997).
4. Couse, J.F., Lindzey, J., Grandien, K., Gustafsson, J.A., and Korach, K.S. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138, 4613-4621 (1997).
5. Couse, J.F. and Korach, K.S. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 20, 358-417 (1999). This review is the most comprehensive paper to date describing the physiological consequences of genetic deletion of ERα and ERβ.
6. Hall, J.M. and McDonnell, D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578 (1999). This article was the first to show that that the estrogen receptor-β (ERβ) subtype of the human ERs could function as a negative regulator of ERα activity and decrease overall cellular sensitivity to estrogens.
7. Katzenellenbogen, B.S., Sun, J., Harrington, W.R., Kraichely, D.M., Ganessunker, D., and Katzenellenbogen, J.A. Structure-function relationships in estrogen receptors and the characterization of novel selective estrogen receptor modulators with unique pharmacological profiles. Ann. N.Y. Acad. Sci. 949, 6-15 (2001).
8. Tzukerman, M.T., Esty, A., Santiso-Mere, D., Danielian, P., Parker, M.G., Stein, R.B., Pike, J.W., and McDonnell, D.P. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol. Endocrinol. 8, 21-30 (1994).
9. Smith, C.L. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58, 627-632 (1998).
10. Kushner, R.J., Agard, D.A., Greene, G.L., Scanlan, T.S., Shiau, A.K., Uht, R.M., and Webb, P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317 (2000).
11. Gill, G., and Ptashne, M. Negative effects of the transcriptional activator GAL4. Nature 334, 721-724 (1988).
12. Meyer, M.-E.,Gronemeyer, H., Turcotte, B., Bocquel, M.T., Tasset, D., and Chambon, P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 57, 433-442 (1989). This article provided compelling evidence for the existence of cofactors by demonstrating that nuclear receptors compete for limiting transcriptional proteins in cells.
13. Halachmi, S., Marden, E., Martin, G., MacKay, H., Abbondanza, C., and Brown, M. Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription. Science 264, 1455-1458 (1994). This article reports the cloning of the first nuclear receptor AF-2 interacting proteins.
14. McKenna, N.J., Lanz, R.B., and O'Malley, B.W. Nuclear receptor coregulators: Cellular and molecular biology. Endocr. Rev. 20, 321-344 (1999). This review provides an excellent and comprehensive description of advances made in understanding the mechanisms of coactivator and corepressor action and the role of these proteins in nuclear receptor pharmacology.
15. Onate, S.A., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. Sequence and characterization of a coactivator for the steroid hormone receptor super-family. Science 270, 1354-1357 (1995). This article reports the identification of the first bona fide nuclear receptor transcriptional coactivator, SRC-1.
16. McDonnell, D.P. and Norris, J.D. Connections and regulation of the human estrogen receptor. Science 296, 1642-1644 (2002).
17. Spencer, T.E., Jenster, G., Burcin, M.M. et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389, 194-198 (1997). This article was the first to report that SRC-1 possesses histone acetyl-transferase activity, which enables it to potentiate nuclear receptor transcriptional activity by catalyzing chromatin decondensation.
18. Feng, W., Ribeiro, R.C., Wagner, R.L., Nguyen, H., Apriletti, J.W., Fletterick, R.J., Baxter, J.D., Kushner, P.J., and West, B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280, 1747-1749 (1998).
19. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A., Greene, G.L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927-937 (1998). This article describes the use of crystallography to show that ER agonists and antagonists alter the structure of the ligand-binding domain of the receptor in a manner that can facilitate (agonists) or prevent (antagonists) coactivator binding.
20. Heery, D.M., Kalkhoven, E., Hoare, S., and Parker, M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387, 733-736 (1997). This article reports identification of a conserved domain within AF-2 coactivators, the LXXLL motif, which is necessary and sufficient to mediate their interaction with nuclear receptors.
21. Chang, C., Norris, J.D., Gron, H., Paige, L.A., Hamilton, P.T., Kenan, D.J., Fowlkes, D., McDonnell, D.P. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta. Mol. Cell Biol. 19, 8226-8239 (1999). This article reports the use of phage display technology to identify peptide antagonists of the ERs and demonstrate that sequences flanking LXXLL motifs of coactivators are important in determining nuclear receptor specificity.
22. McInerney, E.M., Rose, D.W., Flynn, S.E. et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev. 12, 3357-3368 (1998).
23. Lanz, R.B., McKenna, N.J., Onate, S.A., Albrecht, U., Wong, J., Tsai, S.Y., Tsai, M.J., and O'Malley, B.W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97, 17-27 (1999).
24. Endoh, H., Maruyama, K., Masuhiro, Y. et al. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell Biol. 19, 5363-5372 (1999).
25. Stallcup, M.R., Chen, D., Koh, S.S., Ma, H., Lee, Y.H., Li, H., Schurter, B.T, and Aswad DW. Co-operation between protein-acetylating and protein-methylating co-activators in transcriptional activation. Biochem Soc. Trans. 28, 415-418 (2000).
26. Kim, J.H., Li, H., and Stallcup, M.R. CoCoA, a nuclear receptor coactivator which acts through an N-terminal activation domain of p160 coactivators. Mol. Cell 12, 1537-1549 (2003).
27. McKenna, N.J. and O'Malley, B.W. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474 (2002).
28. Tcherepanova, I., Puigserver, P., Norris, J.D., Spiegelman, B.M., and McDonnell, D.P. Modulation of estrogen receptor-alpha transcriptional activity by the coactivator PGC-1. J. Biol. Chem. 275, 16302-16308 (2000).
29. Smith, C.L. and O'Malley, B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25, 45-71 (2004).
30. Dowhan, D.H., Hong, E.P., Auboeuf, D., Dennis, A.P., Wilson, M.M., Berget, S.M., and O'Malley, B.W. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol. Cell 17, 429-439 (2005).
31. Martini, P.G., Delage-Mourroux, R., Kraichely, D.M., and Katzenellenbogen, B.S. Prothymosin alpha selectively enhances estrogen receptor transcriptional activity by interacting with a repressor of estrogen receptor activity. Mol. Cell Biol. 20, 6224-6232 (2000).
32. Chen, J.D. and Evans, R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454-457 (1995).
33. Horlein, A.J., Naar, A.M., and Heinzel, T. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397-404 (1995).
34. Hu, X. and Lazar, M.A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402, 93-96 (1999).
35. Hu, X. and Lazar, M.A. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol. Metab. 11, 6-10 (2000).
36. Zhang, J., Guenther, M.G., Carthew, R.W., and Lazar, M.A. Proteasomal regulation of nuclear receptor corepressor-mediated repression. Genes Dev. 12, 1775-1780 (1998).
37. Norris, J.D., Fan, D., Sherk, A., and McDonnell, D.P. A negative coregulator for the human ER. Mol. Endocrinol. 16, 459-468 (2002).
38. Tremblay, G.B., Tremblay, A., Labrie, F., and Giguére, V. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor α-β heterodimeric complex. Mol. Cell. Biol. 19, 1919-1927 (1999).
39. Wagner, B.L., Norris, J.D., Knotts, T.A., Weigel, N.L., and McDonnell, D.P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell Biol. 18, 1369-1378 (1998).
40. Wu, R.C., Qin, J., Yi, P., Wong, J., Tsai, S.Y., Tsai, M.J., and O'Malley, BW. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol. Cell 15, 937-949 (2004).
41. Hong, S.H. and Privalsky, M.L. The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol. Cell Biol. 20, 6612-6625 (2000).
42. Lefstin, J.A., and Yamamoto, K.R. Allosteric effects of DNA on transcriptional regulators. Nature 392, 885-888 (1998).
43. Hall, J.M., McDonnell, D.P., and Korach, K.S. Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol. 16, 469-486 (2002). This article was the first to use phage display technology to demonstrate that estrogen response elements induce different conformational changes in the ERs, which is concomitant with differential coactivator recruitment.
44. Cheung, E., Acevedo, M.L., Cole, P.A., and Kraus, W.L. Altered pharmacology and distinct coactivator usage for estrogen receptor-dependent transcription through activating protein-1. Proc. Natl. Acad. Sci. U.S.A. 102, 559-564 (2005).
45. Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843-852 (2000). This article was the first to use chromatin immunoprecipitation (ChIP) technology to demonstrate that there is precise and cyclical assembly of cofactors on ER-responsive promoters.
46. Metivier, R., Penot, G., Hubner, M.R., Reid, G., Brand, H., Kos, M., and Gannon, F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115, 751-763 (2003).
47. Xu, J., Qiu, Y., DeMayo, F.J., Tsai, S.Y., Tsai, M.J., O'Malley, B.W. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279, 1922-1925 (1998).
48. Gehin, M., Mark, M., Dennefeld, C., Dierich, A., Gronemeyer, H., and Chambon, P. The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol. Cell Biol. 22, 5923-37 (2002).
49. Xu, J., Liao, L., Ning, G., Yoshida-Komiya, H., Deng, C., and O'Malley, B.W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc. Natl. Acad. Sci. U.S.A. 97, 6379-6384 (2000).
50. Mark, M., Yoshida-Komiya, H., Gehin, M., Liao, L., Tsai, M.J., O'Malley, B.W., Chambon, P., and Xu, J. Partially redundant functions of SRC-1 and TIF2 in postnatal survival and male reproduction. Proc. Natl. Acad. Sci. U.S.A. 101, 4453-4458 (2004).
51. Park, S.E., Xu, J., Frolova, A., Liao, L., O'Malley, B.W., and Katzenellenbogen, B.S. Genetic deletion of the repressor of estrogen receptor activity (REA) enhances the response to estrogen in target tissues in vivo. Mol. Cell Biol. 25, 1989-1999 (2005).
52. White, R., Leonardsson, G., Rosewell, I., Jacobs, M.A., Milligan, S., and Parker, M. The nuclear receptor co-repressor nrip1 (RIP140) is essential for female fertility. Nat. Med 6, 1368-1374 (2000).
53. Leonardsson, G., Steel, J.H., Christian, M. et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl. Acad. Sci. U.S.A. 101, 8437-8442 (2004).
54. Gao, X., Mohsin, S.K., Gatalica, Z., Fu, G., Sharma, P., and Nawaz, Z. Decreased expression of e6-associated protein in breast and prostate carcinomas. Endocrinology 146, 1707-1712 (2005).
55. Kurebayashi, J., Otsuki, T., Kunisue, H., Tanaka, K., Yamamoto, S., and Sonoo, H. Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clin. Cancer Res. 6, 512-518 (2000).
56. Murphy, L.C., Simon, S.L., Parkes, A., Leygue, E., Dotzlaw, H., Snell, L., Troup, S., Adeyinka, A., and Watson, P.H. Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res 60, 6266-71 (2000).
57. Anzick, S.L., Kononen, J., Walker, R.L. et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968 (1997). This article reports the identification of AIB1, a nuclear receptor coactivator that is overexpressed in breast and ovarian cancers.
58. Torres-Arzayus, M.I., Font de Mora, J., Yuan, J., Vazquez, F., Bronson, R., Rue, M., Sellers, W.R., and Brown, M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274 (2004).
59. Osborne, C.K., Bardou, V., Hopp, T.A. et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst. 95, 353-361 (2003).
60. Lavinsky, R.M., Jepsen, K., Heinzel, T. et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. U.S.A. 95, 2920-2925 (1998).
61. McDonnell, D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10, 301-311 (1999).
62. Love, R.R., Mazess, R.B., Barden, H.S., Epstein, S., Newcomb, P.A., Jordan, V.C., Carbone, P.P., and DeMets, D.L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New Engl. J. Med. 326, 852-856 (1992).
63. Paige, L.A., Christensen, D.J., Gron, H. et al. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc. Natl. Acad. Sci. U.S.A. 96, 3999-4004 (1999).
64. McDonnell, D.P., Clemm, D.L., Hermann, T., Goldman, M.E., and Pike, J.W. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9, 659-668 (1995). This study was the first to show that functionally distinct antiestrogens induce unique conformational changes in ERα.
65. Katzenellenbogen, B.S., and Katzenellenbogen, J.A. Biomedicine. Defining the "S" in SERMs. Science 295, 2380-2381 (2002).
66. Jordan, V.C. and Morrow, M. Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr. Rev. 20, 253-278 (1999).
67. Connor, C.E., Norris, J.D., Broadwater, G., Willson, T.M., Gottardis, M.M., Dewhirst, M.W., and McDonnell, D.P. Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. Cancer Res. 61, 2917-2922 (2001).
68. Huang, H. J., Norris, J. D., and McDonnell, D. P. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol. Endocrinol. 16, 1778-1792 (2002).
69. Smith, C.L., Nawaz, Z., and O'Malley, B.W. Coactivator and corepressor regulation of the agonist/antagonist of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657-666 (1997). This article was among the first to report that alterations in the levels of coactivators and corepressors in cells can alter the pharmacology (i.e. agonist/antagonist) activity of the antiestrogens 4-hydroxytamoxifen.
70. Paech, K., Webb, P., Kuiper, G.G., Nilsson, S., Gustafsson, J., Kushner, P.J., and Scanlan, T.S. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277, 1508-1510 (1997).
71. Zhang, X., Jeyakumar, M., Petukhov, S., and Bagchi, M.K. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12, 513-524 (1998).
72. Chen, T., Xie, W., Agler, M., and Banks, M. Coactivators in assay design for nuclear hormone receptor drug discovery. Assay Drug Dev. Technol. 1, 835-842 (2003).
73. Wijayaratne, A.L., Nagel, S.C., Paige, L.A., Christensen, D.J., Norris, J.D., Fowlkes, D.M., and McDonnell, D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140, 5828-5840 (1999).
74. Hall, J.M., Chang, C.Y., and McDonnell, D.P. Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Mol. Endocrinol. 14, 2010-2023 (2000).
75. Norris, J.D., Paige, L.A., Christensen, D.J., Chang, C.Y., Huacani, M.R., Fan, D., Hamilton, P.T., Fowlkes, D.M., and McDonnell, D.P. Peptide antagonists of the human estrogen receptor. Science 285, 744-746 (1999).
76. Larson, C.J., Osburn, D.L., Schmitz, K., Giampa, L., Mong, S.-M., Marschke, K., Seidel, H.M., Rosen, J., and Negro-Vilar, A. Peptide binding identifies an ERalpha conformation that generates selective activity in multiple in vitro assays. J. Biomol. Screen. 10, 590-598 (2005).
77. Murphy, L.C., Leygue, E., Niu, Y., Snell, L., Ho, S.M., and Watson, P.H. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br. J. Cancer 87, 1411-1416 (2002).
78. Girault, I., Lerebours, F., Amarir, S., Tozlu, S., Tubiana-Hulin, M., Lidereau, R., and Bieche, I. Expression analysis of estrogen receptor α coregulators in breast carcinoma: Evidence that NCOR1 expression is predictive to the response to tamoxifen. Clin. Cancer Res. 9, 1259-1266 (2003).